

## Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort

We read with interest the study by Lee *et al.*<sup>1</sup> The authors conducted a propensity score (PS)-matched analysis of a national South Korean cohort evaluating the association between proton pump inhibitor (PPI) use and SARS-CoV-2 susceptibility (primary outcome) and COVID-19 clinical severity (secondary outcome). Between January and May 2020, 4785 patients tested positive for SARS-CoV-2 (3.6% positivity); 267 current PPI users and 148 former PPI users were 1:1 PS-matched to non-users for the secondary outcomes. The authors reported current PPI use versus non-use was associated with a statistically significant increased risk of the composite endpoints: (1) oxygen therapy, intensive care unit (ICU) admission, mechanical ventilation use or death (composite OR 1.63; 95% CI, 1.03–2.53); and (2) ICU admission, mechanical ventilation or death (composite OR 1.79; 95% CI, 1.30 to 3.10).

We assembled a national retrospective cohort of US veterans who tested positive for SARS-CoV-2 (index date). Current outpatient PPI use up to and including the index date (primary exposure) was compared with non-use, defined as no PPI prescription fill in the 365 days prior to the index date (online supplemental figure 1). The primary composite outcome was mechanical ventilation use or death within 60 days; the secondary composite outcome also included hospital or ICU admission. In contrast to PS matching, PS weighting allowed inclusion of all patients. Weighted logistic regression models evaluated severe COVID-19

outcomes between current PPI users versus non-users.

Our analytic cohort included 97 674 veterans with SARS-CoV-2 testing, of whom 14 958 (15.3%) tested positive (6262 (41.9%) current PPI users, 8696 (58.1%) non-users). In the unweighted cohort, current PPI users were older, more often current or former smokers, and had more comorbidities than non-users. After weighting, all covariates were balanced (table 1, online supplemental figure 2). In the unweighted cohort, we observed higher odds of the primary (9.3% vs 7.5%; OR 1.27; 95% CI, 1.13-1.43) and secondary (25.8% vs 21.4%; OR 1.27; 95% CI, 1.18-1.37) composite outcomes among PPI users versus non-users (figure 1, online supplemental table 1). After PS weighting, PPI use versus non-use was not associated with the primary (8.2% vs 8.0%; OR 1.03; 95% CI, 0.911-1.16) or secondary (23.4% vs 22.9%; OR 1.03; 95% CI, 0.95-1.12) composite outcomes. There were no significant interactions between age and PPI use on composite or individual outcomes.

Disparate results are reported in studies analysing COVID-19-related outcomes among PPI users versus non-users<sup>2-6</sup> due to varied PPI exposure definitions; COVID-19 severity outcomes; covariate assessment and adjustment; study design and populations; contemporaneous treatments; and health-care infrastructure. In our unweighted analysis, we also observed an association between PPI use and severe COVID-19 outcomes (separately and as composites) which was not demonstrated in the PS-weighted cohort, suggesting that the associations in previous studies might reflect incomplete covariate adjustment.<sup>7</sup> Indeed, the low E-values (all <2.0) for the weak associations between PPI exposure and COVID-19 severity outcomes (although variably defined) that are demonstrated in previous studies suggest incomplete covariate adjustment and residual confounding (see online supplemental material).<sup>8</sup> Similar to the Lee *et al* study, prior studies also include data from the first months of the COVID-19 pandemic, when management and available treatments were rapidly evolving. Lee *et al*'s outcome definition also included oxygen therapy. Oxygen administration may not correlate with COVID-19 severity and may be considered routine protocol, especially early in the pandemic. Similarly, ICU admission may be influenced by health system factors, such as bed availability. Our study was designed to avoid immortal time, lag time and protopathic biases, which have been present in some PPI studies (see online supplemental material).<sup>9</sup> We further accounted for the pandemic time-frame and clinical management evolution by

**Table 1** Characteristics of veterans with positive SARS-CoV-2 testing, stratified by current PPI user versus PPI non-user


Covariates	Unweighted cohort of veterans with positive SARS-CoV-2 test		Weighted cohort of veterans with positive SARS-CoV-2 test		SMD†
	PPI non-users (n=8696)	Current PPI users (n=6262)	PPI non-users (n=8696)	Current PPI users (n=6262)	
VHA facility‡	‡	‡	‡	‡	0.070
Age, mean years (SD)	60.46 (15.77)	64.37 (13.42)	61.94 (15.14)	62.15 (14.52)	0.014
Male sex, n (%)	7382 (84.9)	5578 (89.1)	7529 (86.6)	5441 (86.9)	0.009
Race/ethnicity, n (%)					0.033
Non-Hispanic white	4437 (51.0)	3885 (62.0)	4757 (54.7)	3527 (56.3)	
Non-Hispanic black	2243 (25.8)	1315 (21.0)	2125 (24.4)	1477 (23.6)	
Non-Hispanic other or unknown	794 (9.1)	515 (8.2)	764 (8.8)	540 (8.6)	
Hispanic	1222 (14.1)	547 (8.7)	1049 (12.1)	717 (11.5)	
Days from 1 January 2020 to index date, mean (SD)*	282 (82.8)	289 (78.7)	285 (81.5)	285 (81.2)	0.005
Smoking status, n (%)					0.067
Current smoker	1030 (11.8)	754 (12.0)	1047 (12.0)	762 (12.2)	
Former smoker	3441 (39.6)	3085 (49.3)	3773 (43.4)	2780 (44.4)	
Never smoker	3430 (39.4)	2180 (34.8)	3260 (37.5)	2376 (37.9)	
Unknown	795 (9.1)	243 (3.9)	616 (7.1)	344 (5.5)	
Comorbidities, n (%)					
Asthma	629 (7.2)	685 (10.9)	747 (8.6)	571 (9.1)	0.018
Coronary artery disease	1645 (18.9)	1911 (30.5)	2034 (23.4)	1500 (24.0)	0.013
Cancer	1770 (20.4)	1750 (27.9)	2020 (23.2)	1508 (24.1)	0.020
Cardiomyopathy	255 (2.9)	279 (4.5)	309 (3.5)	228 (3.6)	0.005
Charlson comorbidity index, mean (SD)	1.82 (2.22)	2.55 (2.54)	2.12 (2.38)	2.17 (2.40)	0.022
Congestive heart failure	621 (7.1)	746 (11.9)	791 (9.1)	582 (9.3)	0.007
Chronic lung disease	2652 (30.5)	2757 (44.0)	3129 (36.0)	2315 (37.0)	0.020
Chronic neuromuscular disease	394 (4.5)	323 (5.2)	420 (4.8)	308 (4.9)	0.004
Chronic kidney disease	1161 (13.4)	1219 (19.5)	1390 (16.0)	1026 (16.4)	0.011
Chronic kidney failure	153 (1.8)	151 (2.4)	180 (2.1)	130 (2.1)	0.001
Chronic obstructive pulmonary disease	1316 (15.1)	1646 (26.3)	1694 (19.5)	1270 (20.3)	0.020
Cerebrovascular disease	2800 (32.2)	2966 (47.4)	3320 (38.2)	2453 (39.2)	0.021
Diabetes	3070 (35.3)	2815 (45.0)	3415 (39.3)	2469 (39.4)	0.003
Drug dependency	379 (4.4)	345 (5.5)	416 (4.8)	311 (5.0)	0.008
Emphysema	126 (1.4)	170 (2.7)	171 (2.0)	126 (2.0)	0.003
Heart disease	2093 (24.1)	2281 (36.4)	2533 (29.1)	1846 (29.5)	0.008
Heart failure (non-congestive)	790 (9.1)	898 (14.3)	988 (11.4)	709 (11.3)	0.001
<i>Helicobacter pylori</i> positive	1841 (21.2)	1138 (18.2)	1746 (20.1)	1232 (19.7)	0.022
HIV	120 (1.4)	51 (0.8)	105 (1.2)	78 (1.2)	0.003
Hypertension	5075 (58.4)	4620 (73.8)	5616 (64.6)	4149 (66.3)	0.035
Lower respiratory infection	1010 (11.6)	855 (13.7)	1076 (12.4)	796 (12.7)	0.010
Obstructive sleep apnea	2884 (33.2)	2773 (44.3)	3254 (37.4)	2454 (39.2)	0.037
Medications, n (%)					
ACE inhibitors	2233 (25.7)	2152 (34.4)	2549 (29.3)	1887 (30.1)	0.018
ARBs	1170 (13.5)	1239 (19.8)	1378 (15.8)	1036 (16.6)	0.019
H2RAs	626 (7.2)	423 (6.8)	638 (7.3)	459 (7.3)	0.001
NSAIDs	5359 (61.6)	4745 (75.8)	5812 (66.8)	4358 (69.6)	0.059
Statins	4176 (48.0)	4249 (67.9)	4832 (55.6)	3656 (58.4)	0.057

\*This variable represents the days from 1 January 2020 to the index date of SARS-CoV-2 testing to account for temporal differences.

†Only SMDs for the weighted cohort are provided in this table. Please refer to online supplemental figure 1 for the SMD plots for both the unweighted and weighted cohorts.

‡All of the 127 VHA facilities were included as covariates in this analysis; however, the proportion of patients at each station for each group is not listed here due to space considerations. The SMD between PPI users and non-users in the unweighted cohort was 0.36, with balance achieved after weighting (SMD: 0.07).

ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; H2RAs, histamine-2 receptor antagonists; NSAIDs, non-steroidal anti-inflammatory agents; PPI, proton-pump inhibitor; SMD, standardised mean difference; VHA, Veterans Health Administration.



**Figure 1** Forest plot of primary and secondary COVID-19 outcomes within 60 days of the index date, weighted and unweighted cohorts (semi-log scale, range 0.1 to 10). In the unweighted cohort, current outpatient PPI use compared with PPI non-user was associated with increased odds of severe COVID-19 outcomes, defined based on composite (primary: death or mechanical ventilation; secondary: death, mechanical ventilation, ICU admission or hospitalisation) and individual component outcomes. Each of these associations were statistically non-significant after more fully accounting for covariates in the propensity-weighted cohort, including date of SARS-CoV-2 testing and VHA facility location. Of note, there was no significant interaction between age group and PPI use on these outcomes. ICU, intensive care unit; PPI, proton pump inhibitor.

considering COVID-19 prevalence and US geography.

In conclusion, with respect to COVID-19, our robust PS-weighted analysis provides patients and providers with further evidence for PPI safety.

Shailja Shah<sup>1,2</sup>, Alese Halvorson,<sup>3</sup> Brandon McBay,<sup>4</sup> Chad Dorn,<sup>5</sup> Otis Wilson,<sup>6,7</sup> Sony Tuteja,<sup>8,9</sup> Kyong-Mi Chang,<sup>8,9</sup> Kelly Cho,<sup>10,11</sup> Richard Hauger,<sup>12,13</sup> Ayako Suzuki,<sup>14,15</sup> Christine Hunt,<sup>14,15</sup> Edward Siew,<sup>7,16</sup> Michael Matheny,<sup>5,7,16</sup> Adriana Hung<sup>6,16</sup> Robert Greevy,<sup>3,6</sup> Christianne Roumie<sup>6,17,18</sup>

<sup>1</sup>Gastroenterology Section, VA San Diego Healthcare System, San Diego, California, USA

<sup>2</sup>Division of Gastroenterology, University of California, San Diego, California, USA

<sup>3</sup>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA

<sup>4</sup>Department of Public Health, Harvard University T H Chan School of Public Health, Boston, Massachusetts, USA

<sup>5</sup>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA

<sup>6</sup>Clinical Services Research and Development, VA Tennessee Valley, Nashville, TN, USA

<sup>7</sup>Health Services Research and Development, VA Tennessee Valley, Nashville, Tennessee, USA

<sup>8</sup>The Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA

<sup>9</sup>University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

<sup>10</sup>VA Boston Healthcare System, Boston, Massachusetts, USA

<sup>11</sup>Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

<sup>12</sup>Department of Psychiatry, University of California San Diego, La Jolla, California, USA

<sup>13</sup>Center of Excellence for Stress & Mental Health, VA San Diego Healthcare System, San Diego, California, USA

<sup>14</sup>Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA

<sup>15</sup>Gastroenterology Section, Durham VA Health Care System, Durham, North Carolina, USA

<sup>16</sup>Division of Nephrology & Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA

<sup>17</sup>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

<sup>18</sup>VA Geriatrics Research Education and Clinical Center (GRECC), VA Tennessee Valley Health System, Nashville, Tennessee, USA

**Correspondence** to Dr Shailja Shah, Gastroenterology, VA San Diego Healthcare System, La Jolla, CA 92161, USA; s6shah@health.ucsd.edu

**Acknowledgements** Jason Denton (in memoriam): We would like to acknowledge and remember Jason Denton, a friend, colleague and team member, who contributed to database development and data stewardship.

**Contributors** SS helped in study concept, study design, dataset verification, interpretation of data and statistical analysis, drafting of initial manuscript and critical revision of the manuscript. AH and RG were responsible for study design, primary statistical analysis, dataset verification, interpretation of data and statistical analysis, critical revision of the manuscript and methodological oversight. CD and OW helped in dataset creation and stewardship. BM, ST, KC, AS, CH, ES, MM and AH performed manuscript revision. CR helped in study design, interpretation of data and statistical analysis, methodological and study oversight and critical revision of manuscript. All authors approved the final version of the manuscript.

**Funding** American Gastroenterological Association 2019 Research Scholar Award (SS); US Dept of Veterans Affairs ICX002027A01 (SS), Million Veteran Programme

Core MVP000 (KC); National Institute of Health K23HL143161A01 (ST).

**Competing interests** The authors report no conflicts of interest that are relevant to this article. Dr. Shah is an ad hoc consultant for Phathom Pharmaceuticals.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This article is made freely available for personal use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2021-325701>).



**To cite** Shah S, Halvorson A, McBay B, et al. *Gut* 2022;**71**:1447–1450.

Received 22 July 2021

Accepted 5 October 2021

Published Online First 18 October 2021

*Gut* 2022;**71**:1447–1450. doi:10.1136/gutjnl-2021-325701

#### ORCID iDs

Shailja Shah <http://orcid.org/0000-0002-2049-9959>

Adriana Hung <http://orcid.org/0000-0002-3203-1608>

#### REFERENCES

- Lee SW, Ha EK, Yeniova Abdullah Özgür, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. *Gut* 2021;**70**:76–84.
- Kamal F, Khan MA, Sharma S, et al. Lack of consistent associations between pharmacologic gastric acid suppression and adverse outcomes in patients with coronavirus disease 2019: meta-analysis of observational studies. *Gastroenterology* 2021;**160**:2588–90.
- Kow CS, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. *J Intern Med* 2021;**289**:125–8.
- Hariyanto TI, Prasetya IB, Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. *Dig Liver Dis* 2020;**52**:1410–2.
- Li G-F, An X-X, Yu Y, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? a meta-analysis. *Gut* 2021;**70**:1806–8.
- Israelsen SB, Ernst MT, Lundh A, et al. Proton pump inhibitor use is not strongly associated with SARS-CoV-2

- related outcomes: a nationwide study and meta-analysis. *Clin Gastroenterol Hepatol* 2021;19:1845–54.
- 7 Etminan M, Nazempour M, Candidate MS, *et al*. Potential biases in studies of acid-suppressing drugs and COVID-19 infection. *Gastroenterology* 2021;160:1443–6.
  - 8 VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. *Ann Intern Med* 2017;167:268–74.
  - 9 Suissa S, Suissa A. Proton-pump inhibitors and increased gastric cancer risk: time-related biases. *Gut* 2018;67:2228–9.